1. Home
  2. CULP vs BOLD Comparison

CULP vs BOLD Comparison

Compare CULP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Culp Inc.

CULP

Culp Inc.

N/A

Current Price

$3.47

Market Cap

46.2M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.50

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CULP
BOLD
Founded
1972
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
46.2M
54.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
CULP
BOLD
Price
$3.47
$2.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.9K
★ 115.4K
Earning Date
12-09-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 47.06
32.47
EPS
★ 0.47
N/A
Revenue
★ $203,482,000.00
N/A
Revenue This Year
$3.15
N/A
Revenue Next Year
$1.77
N/A
P/E Ratio
$7.47
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.70
$0.96
52 Week High
$4.17
$3.16

Technical Indicators

Market Signals
Indicator
CULP
BOLD
Relative Strength Index (RSI) 43.36 50.04
Support Level $3.46 $2.43
Resistance Level $3.48 $2.65
Average True Range (ATR) 0.17 0.10
MACD -0.02 0.02
Stochastic Oscillator 37.41 43.18

Price Performance

Historical Comparison
CULP
BOLD

About CULP Culp Inc.

Culp Inc manufactures, sources, and markets mattress fabrics, sewn covers for mattresses, foundations, and other bedding products, and upholstery fabrics, including cut and sewn kits, for residential, commercial, and hospitality furniture and other applications. It markets fabrics produced at its manufacturing facilities and fabrics sourced through other suppliers to bedding and furniture companies. Its products serve the bedding, residential furnishings, commercial furnishings, and hospitality furnishings markets. Its segments are: Bedding and Upholstery, with Bedding generating the maximum revenue. The Bedding segment supplies the bedding market, comprising mattress sets and bedding accessory products. It generates the maximum revenue from the United States.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: